An Investigation into the Intake of A Postbiotic – Salavans® on the Improvement of Well-Being on Adults with Self-Reported Throat Discomfort: A PilotScale Study |Biomedgrid

The complex composition of microbial community in oropharynx makes the etiology and pathology of pharynx discomfort and illness complicated and recalcitrant. Regular antibiotic treatment manifests several limitations such as antibiotic resistance and disease recurrence. In previous in vitro research, a postbiotic named Salavans®, screened and selected from over 800 lactic bacteria, could aggregate and compete with Streptococcus pyogenes (S. pyogenes), which is the common and dominant cause of pharyngitis and tonsilitis. In our study, we conducted a clinical trial by orally supplementing Salavans contained formula to individuals with self-reported pharynx discomfort for 7 days. The discomforts including coughing, dryness, itchiness and so on were relieved while no adverse events were reported. By characterizing the microbial community composition in the pharynx using 16s rDNA sequencing, it was observed that the relative abundance of certain pathogenic bacteria genera such as Streptococcus, Neisseria and Prevotella were significantly reduced. Therefore, it is concluded the administration of Salavan not only could reduce the specifically targeted Streptococcus but also could alter the microbiota composition in pharynx to a healthy state.